secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2025-06-10T23:59:59+00:00
Accession:  0000950170-25-084098
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome launches SYMBRAVO for acute migraine treatment in U.S.
-------------------------------------------------------------

- SYMBRAVO (meloxicam/rizatriptan) now available by prescription for acute migraine with or without aura in adults.
- Novel multi-mechanistic approach targeting multiple migraine pathways; rapid pain freedom at 2 hours vs placebo, sustained up to 24 hours.
- Axsome launches SYMBRAVO On My Side patient support program including savings card for eligible patients.
- SYMBRAVO uses Axsome's patented MoSEIC technology; migraine affects ~40M Americans, 63% not satisfied with current treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025084098/0000950170-25-084098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017025084098/axsm-20250610.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-084098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer